KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Jazz Pharmaceuticals (JAZZ) Other Operating Expenses (2016 - 2025)

Jazz Pharmaceuticals has reported Other Operating Expenses over the past 16 years, most recently at $323.3 million for Q4 2025.

  • Quarterly results put Other Operating Expenses at $323.3 million for Q4 2025, up 12.4% from a year ago — trailing twelve months through Dec 2025 was $1.8 billion (up 70.52% YoY), and the annual figure for FY2025 was $2.1 billion, up 94.44%.
  • Other Operating Expenses for Q4 2025 was $323.3 million at Jazz Pharmaceuticals, down from $339.7 million in the prior quarter.
  • Over the last five years, Other Operating Expenses for JAZZ hit a ceiling of $1.2 billion in Q2 2025 and a floor of $108.4 million in Q1 2021.
  • Median Other Operating Expenses over the past 5 years was $287.4 million (2022), compared with a mean of $351.4 million.
  • Biggest five-year swings in Other Operating Expenses: crashed 74.79% in 2021 and later surged 346.48% in 2025.
  • Jazz Pharmaceuticals' Other Operating Expenses stood at $293.4 million in 2021, then soared by 131.64% to $679.8 million in 2022, then tumbled by 59.28% to $276.8 million in 2023, then grew by 3.91% to $287.6 million in 2024, then increased by 12.4% to $323.3 million in 2025.
  • The last three reported values for Other Operating Expenses were $323.3 million (Q4 2025), $339.7 million (Q3 2025), and $1.2 billion (Q2 2025) per Business Quant data.